CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO Price Prediction) now offers a more compelling setup than GLP-1 category leader Eli Lilly (NYSE:LLY) after a peak-to-current decline of roughly 68% from Novo’s mid-2024 high near $127 to recent levels near $40. The … Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.